Financial Performance - The company's operating revenue for 2022 was ¥157,678,436.36, a decrease of 33.15% compared to ¥235,878,772.67 in 2021[34]. - The net profit attributable to shareholders for 2022 was ¥14,873,108.35, down 75.99% from ¥61,945,412.84 in 2021[34]. - The gross profit margin for 2022 was 72.46%, slightly down from 74.90% in 2021[34]. - The total assets at the end of 2022 were ¥646,151,101.29, a decrease of 6.02% from ¥687,534,613.17 at the end of 2021[35]. - The company's debt-to-asset ratio increased to 25.05% in 2022 from 21.90% in 2021[35]. - The basic earnings per share for 2022 was ¥0.05, down 88.37% from ¥0.43 in 2021[34]. - The company achieved an operating revenue of CNY 157.68 million, a year-on-year decrease of 33.15%, and a net profit of CNY 14.87 million, down 75.99% year-on-year, largely due to multiple COVID-19 outbreaks in Hohhot affecting sales in the typically strong fourth quarter[50]. - The company's operating profit decreased by 88.04% year-on-year, primarily due to the decline in operating revenue[63]. Investments and Projects - In December 2022, the company decided to increase investment in the "Dagang Pharmaceutical Health Technology Industrial Park Project," raising the total investment to 358 million RMB[6]. - The company plans to invest CNY 358 million in the construction of the "Dagang Pharmaceutical Health Technology Industrial Park," which will include 13 production lines to enhance production capacity and product quality[51]. - The company has invested ¥111,121,527.44 in the 大唐药业健康科技产业园区 project, with a cumulative investment of ¥227,880,692.71, currently at 75% completion[77]. - The project "Dagang Pharmaceutical Health Technology Industrial Park" has an investment progress of 72.48% as of the reporting date[163]. - The company has fully utilized RMB 723,729.20 for the marketing system construction and brand promotion project, achieving 100% investment progress[163]. Research and Development - The company completed the research and development project "Mongolian Medicine Warming Palace Seven Flavor Powder" in April 2022, which passed the acceptance by the Hohhot Science and Technology Bureau[6]. - The company is engaged in multiple R&D projects aimed at developing new health products and improving existing product efficacy, which are expected to enhance the company's competitive edge in the market[92]. - R&D expenditure amounted to ¥6,541,826.84, a decrease from ¥7,388,334.03 in the previous period, with R&D spending as a percentage of operating income increasing from 3.13% to 4.15%[88]. - The total number of R&D personnel decreased from 26 to 23, with the proportion of R&D staff to total employees rising from 10.22% to 12.21%[89]. - The company holds a total of 19 patents, including 3 invention patents, maintaining the same number of patents as the previous period[90]. Market and Sales Strategy - The company aims to strengthen its marketing system and brand promotion to expand market coverage and improve brand recognition in response to business development and market expansion needs[52]. - The company aims to enhance its market share in the hospital system and OTC sectors for Mongolian medicine products[107]. - The company plans to deepen channel penetration for specialty OTC products and strengthen partnerships with top 100 chain terminals[107]. - The company will increase marketing investments and improve the professionalism and effectiveness of its marketing team[108]. - The company is enhancing its sales market for other products to reduce the impact of single product volatility on operating performance[117]. Risk Factors - The company faces risks related to drug price reductions, which may impact its revenue and profit due to ongoing government price controls in the pharmaceutical market[14]. - The company has adjusted its risk assessment and no longer considers the impact of COVID-19 on its operational performance as a major risk[21]. - The company is exposed to raw material price fluctuations, particularly for traditional Chinese medicine materials, which could affect production costs[115]. - The company’s product "Sea Buckthorn Syrup" was included in the SCI international journal "Plant Chemistry Letters" in October 2022[6]. - The company is positioned to benefit from national policies supporting traditional Chinese medicine, which may enhance its market opportunities in the future[55]. Corporate Governance - The company is controlled by Hohhot Renhe Real Estate Development Co., Ltd. with no other concerted actions[28]. - The company’s legal representative is Hao Yantao[24]. - The company has maintained stable management with no changes in the Chairman, General Manager, or Chief Financial Officer during the reporting period[178]. - The company’s board consists of 8 members and the supervisory board has 3 members[177]. - The company has established a compensation and assessment committee responsible for formulating performance evaluation standards for directors and senior management[182]. Shareholder Information - The company reported a total of 14,933,877 shares held by directors and senior management, representing 5.7214% of total shares[177]. - The largest shareholder, Renhe Real Estate Development Co., Ltd., holds 154,329,462 shares, representing 59.13% of total shares[150]. - The total number of shareholders is 11,859[146]. - The actual controller, Hao Yantao, holds 99% of the shares in the controlling shareholder, Renhe Real Estate[152]. Compliance and Regulations - The company is committed to strict compliance with national drug supervision regulations to mitigate regulatory risks[112]. - The company has established a quality management system in compliance with GMP standards to mitigate risks related to drug quality and safety[119]. - The company has no significant litigation or arbitration matters during the reporting period[128]. - The company has disclosed that there are no violations in the use and disclosure of raised funds[160].

Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 54,218,554.17, representing a significant year-on-year growth of 90.34% from CNY 28,484,733.38 in the same period of 2022[11] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 7,507,383.78, up 35.01% from CNY 5,560,706.73 in the previous year[11] - The net profit after deducting non-recurring gains and losses increased by 76.55% year-on-year, totaling CNY 6,556,365.88 compared to CNY 3,713,600.84 in Q1 2022[11] - Total operating revenue for Q1 2023 reached ¥54,218,554.17, a significant increase from ¥28,484,733.38 in Q1 2022, representing a growth of approximately 90.5%[36] - Net profit for Q1 2023 was ¥7,507,383.78, up from ¥5,560,706.73 in Q1 2022, reflecting a growth of approximately 34.9%[38] - The company's operating profit for Q1 2023 was 9,285,673.78, an increase from 7,377,144.09 in Q1 2022, representing a growth of approximately 25.0%[41] - Net profit for Q1 2023 reached 7,953,370.72, compared to 6,343,145.47 in Q1 2022, indicating a year-over-year increase of about 25.4%[41] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 647,557,603.95, a slight increase of 0.22% compared to CNY 646,151,101.29 at the end of 2022[11] - The company's current assets totaled CNY 279,072,405.33, down from CNY 308,402,565.52 at the end of 2022, representing a decrease of approximately 9.5%[28] - The company's total assets amounted to ¥643,171,678.51, slightly up from ¥641,323,978.78 in the previous period[34] - Total liabilities decreased to CNY 157,759,454.90 from CNY 163,510,076.69, a reduction of about 3.5%[30] - Current liabilities decreased to ¥143,374,569.57 from ¥154,886,303.12, showing a reduction of about 7.8%[34] - Non-current liabilities increased to ¥11,514,398.74 from ¥5,758,076.85, representing a growth of approximately 100.5%[34] - The total equity of the company rose to ¥488,282,710.20 from ¥480,679,598.81, indicating an increase of about 1.3%[34] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 26,353,571.31, a decrease from a net inflow of CNY 66,622,261.16 in the same period last year[12] - The net cash flow from operating activities in Q1 2023 was -26,353,571.31, a decline from 66,622,261.16 in Q1 2022, indicating a negative shift in cash flow[45] - The cash flow from financing activities in Q1 2023 was 24,363,359.99, a recovery from a negative cash flow of -4,671,240.91 in Q1 2022[45] - Cash inflow from financing activities increased to $32.24 million in Q1 2023 compared to $7.25 million in Q1 2022[47] - The net cash flow from financing activities improved to $24.36 million in Q1 2023 from -$4.67 million in Q1 2022[47] Shareholder Information - The number of shareholders holding more than 5% of shares includes 呼和浩特市仁和房地产开发有限公司 with 59.13% ownership[21] - The company reported a basic earnings per share of CNY 0.03, a decrease of 25.00% compared to CNY 0.04 in the same period last year[12] - Basic earnings per share for Q1 2023 were ¥0.03, unchanged from Q1 2022[38] - Basic earnings per share for Q1 2023 were 0.03, down from 0.04 in Q1 2022, reflecting a decrease in profitability on a per-share basis[42] Operational Costs - Total operating costs for Q1 2023 were ¥46,672,715.03, compared to ¥25,082,838.87 in Q1 2022, indicating an increase of about 86.5%[37] - The total operating expenses for Q1 2023 were 64,836,994.19, compared to 38,027,515.41 in Q1 2022, showing an increase in operational costs[45] Research and Development - Research and development expenses for Q1 2023 were ¥1,286,808.01, compared to ¥1,487,606.90 in Q1 2022, showing a decrease of approximately 13.5%[37] - The company incurred research and development expenses of 1,191,958.30 in Q1 2023, slightly up from 1,125,728.74 in Q1 2022, indicating continued investment in innovation[41] Other Information - The company has fulfilled its commitments as disclosed in the public offering prospectus dated July 16, 2020[24] - The company has not engaged in any significant litigation or arbitration matters during the reporting period[24] - There were no new major acquisitions or mergers reported in the current quarter[25] - Non-recurring gains and losses for the first quarter totaled CNY 951,017.90 after tax, with government subsidies contributing CNY 660,417.98[15]

Financial Performance - The company's operating revenue for 2022 was CNY 157,696,440, a decrease of 33.15% compared to the previous year[3] - Net profit attributable to shareholders was CNY 14,107,469, down 77.23% year-on-year[3] - Basic earnings per share decreased to CNY 0.05, representing an 88.37% decline from the previous year[3] - Total assets at the end of the reporting period were CNY 646,451,202, a decrease of 5.98% year-on-year[5] - Shareholders' equity attributable to the company was CNY 481,875,385.76, down 10.26% compared to the beginning of the year[5] - The company's net asset per share decreased to CNY 1.85, a 50% decline year-on-year[5] Impact of COVID-19 - The decline in revenue and net profit was primarily due to the severe impact of COVID-19 outbreaks in Hohhot, affecting normal production and sales[6] - The company expects normal production operations to resume following the pandemic disruptions[6] Corporate Actions - The company implemented a stock dividend, increasing shares by 80% and distributing CNY 5 cash for every 10 shares held[6] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[7]

Financial Performance - The company's net profit attributable to shareholders for 2022 is expected to be 14.11 million yuan, a decrease of 77.23% compared to 61.95 million yuan in the previous year[3]. - The decline in revenue and net profit is primarily due to the complex and severe COVID-19 prevention and control situation in Hohhot, where the company operates[4]. - The fourth quarter of 2022 saw a significant drop in revenue, which is typically the company's peak sales season, due to the severe impact of the pandemic[5]. - The financial data in the earnings forecast is preliminary and has not been audited by an accounting firm, urging investors to be cautious about investment risks[6].

内蒙古大唐药业股份有限公司 2022 年第三季度报告 证券代码：836433 证券简称：大唐药业 公告编号：2022-109 大唐药业 证券代码 : 836433 内蒙古大唐药业股份有限公司 2022 年第三季度报告 1 | 第一节 | 重要提示 4 | | --- | --- | | 第二节 | 公司基本情况 5 | | 第三节 | 重大事件 12 | | 第四节 | 财务会计报告 14 | 内蒙古大唐药业股份有限公司 2022 年第三季度报告 3 释义项目 释义 公司、本公司、股份公司、大唐药业 指 内蒙古大唐药业股份有限公司 仁和房地产 指 呼和浩特市仁和房地产开发有限公司 股东大会、董事会、监事会 指 股份公司股东大会、董事会、监事会 高级管理人员 指 公司总经理、副总经理、董事会秘书、财务总监以及《公 司章程》规定的人员 保荐机构、中泰证券 指 中泰证券股份有限公司 报告期 指 2022 年 7 月 1 日至 2022 年 9 月 30 日 本报告期初 指 2022 年 7 月 1 日 本报告期末 指 2022 年 9 月 30 日 上年同期 指 2021 年 7 月 1 日至 2021 年 9 月 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 80,791,353.83, a decrease of 23.28% compared to CNY 105,302,839.15 in the same period last year[28]. - The net profit attributable to shareholders of the listed company was CNY 17,053,717.43, down 32.80% from CNY 25,377,387.53 year-on-year[28]. - The net profit after deducting non-recurring gains and losses was CNY 5,652,179.22, a significant decline of 76.04% compared to CNY 23,588,096.91 in the previous year[28]. - The gross profit margin increased to 77.91% from 74.54% year-on-year[28]. - The weighted average return on net assets based on net profit attributable to shareholders was 3.20%, down from 4.86% in the previous year[28]. - The company reported a basic earnings per share of CNY 0.06, a decrease of 64.71% compared to CNY 0.17 in the same period last year[28]. - The total operating income for the first half of 2022 was 78,368,000.00 CNY, with a year-on-year decrease of 25.17% in Northeast China and 14.07% in North China[51]. - The total comprehensive income for the period amounted to CNY 25,377,387.53[148]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 627,992,537.42, down 8.66% from CNY 687,534,613.17 at the end of the previous year[29]. - The total liabilities decreased by 5.94% to CNY 141,603,253.74 from CNY 150,553,281.42 year-on-year[29]. - Current assets totaled CNY 425,531,613.48 as of June 30, 2022, down from CNY 510,914,930.36 at the end of 2021, representing a decrease of approximately 16.7%[123]. - The company's equity attributable to shareholders decreased from CNY 536,981,331.75 to CNY 486,389,283.68, a decrease of about 9.4%[125]. - The total liabilities at the end of the period were not explicitly stated but can be inferred from the equity and asset figures[149]. Cash Flow - The company's cash flow from operating activities was CNY 52,540,997.56, a significant improvement from a negative cash flow of CNY -1,296,807.99 in the same period last year[29]. - The net cash flow from operating activities increased to approximately ¥52.54 million, a significant improvement from a negative cash flow of ¥1.30 million in the first half of 2021[139]. - The net cash flow from investment activities increased by 112,557,111.33 CNY, a significant improvement from -7,043,762.67 CNY in the previous period[55]. - The net cash flow from financing activities was -69,617,016.04 CNY, worsening from -22,229,088.61 CNY in the same period last year, primarily due to increased dividend payments[142]. Research and Development - The company has initiated several key R&D projects, including the "Research and Development of Quality Technical Standards for Classic Chinese-Mongolian Medicine" approved in May 2022[3]. - The company has received approval for the "Research and Industrialization of Generic Fluorometholone Liniment" project, indicating ongoing efforts in product development[3]. - Research and development expenses for the first half of 2022 were CNY 2,797,752.88, down from CNY 3,666,162.56 in the first half of 2021, a decrease of 23.7%[132]. Regulatory and Market Risks - The company is facing risks related to national regulatory policies, drug quality safety, and potential price reductions in the pharmaceutical market, which could impact revenue and profitability[10][11]. - The company is not currently required to conduct consistency evaluations for its products, but future regulatory changes could impose such requirements, affecting sales[12][13]. - The company anticipates a continued trend of drug price reductions in China, impacting revenue and profit margins[62]. - The company is adapting to the challenges and opportunities in the pharmaceutical industry, driven by ongoing healthcare reforms and increasing demand for high-quality pharmaceutical products[39]. Shareholder and Capital Structure - The company completed a cash dividend distribution of RMB 72,632,800.50, distributing RMB 5.00 per 10 shares and increasing the share capital by 116,212,480 shares[3]. - The total number of unrestricted shares increased from 70,009,589 to 169,177,685, representing a rise from 48.19% to 64.70% of total shares[85]. - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 59.02% of the shares, increasing from 85,738,590 shares to 154,329,462 shares[89]. - The company has a commitment to avoid competition and has not engaged in any competitive activities with its subsidiaries, ensuring compliance with its commitments[81]. Employee and Management Changes - The company appointed two new senior executives: Lian Lijun as Executive Vice President and Liu Jia as Vice President, both effective from April and May 2022 respectively[112]. - Total employees increased from 213 to 232, with a net addition of 19 employees during the reporting period[116]. - Core employees decreased from 68 to 64, with 4 core employees leaving the company[118]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 25, 2022[162]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[165]. - The company has not reported any significant asset impairment losses or changes in related party transactions during the reporting period[154].

Financial Performance - Operating revenue for Q1 2022 was CNY 28,484,733.38, representing a decline of 25.62% year-on-year[16] - Net profit attributable to shareholders for Q1 2022 was CNY 5,560,706.73, down 45.09% compared to the same period last year[16] - The net profit after deducting non-recurring gains and losses decreased by 59.02% year-on-year, amounting to CNY 3,713,600.84[16] - Basic earnings per share for Q1 2022 were CNY 0.04, a decrease of 42.86% from CNY 0.07 in Q1 2021[16] - Total operating revenue for Q1 2022 was CNY 28,484,733.38, a decrease of 25.6% compared to CNY 38,297,693.93 in Q1 2021[38] - The net profit for Q1 2022 was CNY 5,560,706.73, down 45.0% from CNY 10,126,885.66 in Q1 2021[40] - The total profit for Q1 2022 was CNY 6,388,303.95, a decline of 47.4% from CNY 12,138,509.83 in Q1 2021[40] - The total comprehensive income for Q1 2022 was CNY 5,560,706.73, a decrease of 45.0% compared to CNY 10,126,885.66 in Q1 2021[40] Cash Flow - The company's cash flow from operating activities was CNY 66,622,261.16, compared to a negative cash flow of CNY 13,814,864.56 in the previous year[16] - The cash inflow from operating activities for Q1 2022 was ¥104,649,776.57, a significant increase from ¥45,079,825.11 in Q1 2021, representing a growth of approximately 132.5%[45] - The net cash flow from operating activities for Q1 2022 was ¥66,622,261.16, compared to a negative cash flow of ¥13,814,864.56 in Q1 2021, indicating a turnaround in operational performance[45] - The total cash inflow from investment activities in Q1 2022 was ¥274,865,172.10, down from ¥382,313,126.27 in Q1 2021, reflecting a decrease of about 28.1%[47] - The net cash flow from investment activities for Q1 2022 was ¥166,654,874.13, a recovery from a negative cash flow of ¥4,024,025.47 in Q1 2021[47] - The cash inflow from financing activities in Q1 2022 was ¥7,247,400.00, a decrease from ¥25,672,750.00 in Q1 2021, showing a decline of approximately 71.7%[47] - The net increase in cash and cash equivalents for Q1 2022 was ¥228,605,661.83, compared to an increase of ¥7,519,488.08 in Q1 2021, indicating a substantial improvement[47] - The ending balance of cash and cash equivalents as of the end of Q1 2022 was ¥245,705,025.88, significantly higher than ¥75,837,833.33 at the end of Q1 2021[47] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 679,354,800.06, a decrease of 1.19% compared to the end of 2021[16] - The asset-liability ratio for the consolidated entity was 20.04%, down from 21.90% at the end of 2021[16] - The total current assets decreased from 510,914,930.36 CNY on December 31, 2021, to 504,256,128.11 CNY on March 31, 2022[30] - The total liabilities decreased from 145,452,319.77 CNY on December 31, 2021, to 131,179,914.74 CNY on March 31, 2022[31] - The company's fixed assets are valued at 86,066,798.79 CNY as of March 31, 2022, down from 88,030,062.33 CNY at the end of 2021[31] - Total liabilities decreased to CNY 135,112,924.39 in Q1 2022 from CNY 149,145,017.47 in Q1 2021, reflecting a reduction of 9.4%[36] - Shareholders' equity increased to CNY 541,645,436.67 in Q1 2022 from CNY 534,641,447.45 in Q1 2021, representing a growth of 1.9%[36] Shareholder Information - The number of ordinary shareholders was 12,888 as of the report date[22] - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 85,738,590 shares, representing 59.02% of total shares[24] - The total shares held by the top ten shareholders amount to 98,258,941, which is 67.63% of the total shares[24] Operational Challenges - The company experienced a significant decline in sales due to reduced foot traffic in pharmacies and outpatient volumes in hospitals caused by the domestic pandemic[17] Research and Development - Research and development expenses increased to CNY 1,487,606.90 in Q1 2022, up 26.9% from CNY 1,171,860.85 in Q1 2021[40] Other Financial Metrics - The company's financial expenses rose significantly to CNY 800,522.41 in Q1 2022, compared to CNY 174,826.76 in Q1 2021[40] - Investment income for Q1 2022 was CNY 2,286,784.99, down 53.5% from CNY 4,913,126.27 in Q1 2021[40] - The company's sales expenses were CNY 11,928,031.13 in Q1 2022, slightly down from CNY 12,440,021.79 in Q1 2021[40] - The company's management expenses decreased to CNY 5,420,978.24 in Q1 2022 from CNY 5,618,307.52 in Q1 2021[40]

Financial Performance - The company's operating revenue for 2021 was CNY 235,878,772.67, representing an increase of 8.25% compared to CNY 217,899,726.83 in 2020[33]. - The net profit attributable to shareholders for 2021 was CNY 61,945,412.84, which is a 1.81% increase from CNY 60,843,631.55 in 2020[33]. - The gross profit margin improved to 74.90% in 2021 from 70.93% in 2020[33]. - The company's net profit growth rate for 2021 was 1.81%, compared to a growth rate of 12.23% in 2020[38]. - The company achieved a revenue of 235.88 million yuan in 2021, representing an increase of 8.25% compared to the previous year[52]. - The net profit for 2021 was 61.95 million yuan, which is a growth of 1.81% year-on-year, primarily driven by the increase in revenue[52]. - The company's cash flow from operating activities decreased significantly by 87.74% to CNY 11,782,297.68 in 2021 from CNY 96,083,470.86 in 2020[37]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 11.83% in 2021, down from 17.30% in 2020[33]. - The basic earnings per share for 2021 was CNY 0.43, a decrease of 14.00% from CNY 0.50 in 2020[33]. - The total revenue for Inner Mongolia Datang Pharmaceutical Co., Ltd. increased by 8.25% year-on-year, with main business revenue growing by 12.02% due to increased product sales[73]. Assets and Liabilities - Total assets increased by 5.67% to CNY 687,534,613.17 at the end of 2021, compared to CNY 650,660,548.98 at the beginning of the year[35]. - The total liabilities rose by 12.55% to CNY 150,553,281.42 at the end of 2021, up from CNY 133,761,583.42 at the beginning of the year[35]. - The company reported a total of CNY 1,062,200,000.00 in financial products, with no overdue amounts or expected impairments[86]. - The total value of pledged assets amounts to 59,556,890.86 CNY, representing 8.66% of total assets[147]. Research and Development - The company holds 19 patents, including 3 invention patents, supporting its competitive edge in the pharmaceutical industry[49]. - Research and development expenses grew by 41.52%, reflecting an increase in R&D projects[66]. - The company reported a total R&D expenditure of ¥7,388,334.03, representing 3.13% of operating revenue, an increase from 2.40% in the previous year[94]. - The company has established collaborations with Tianjin University of Traditional Chinese Medicine and China Pharmaceutical University for various research projects[99]. - The company is addressing potential R&D delays by collaborating with external experts to ensure timely execution of its R&D strategies[114]. Market and Sales Strategy - The company aims to enhance its marketing system and brand promotion to expand market coverage and improve brand recognition[54]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development efforts[182]. - The company is positioned within the pharmaceutical manufacturing sector, benefiting from macroeconomic growth and increasing healthcare demands[195]. - The company is adapting to national procurement policies aimed at promoting innovation within the pharmaceutical industry[196]. - The company continues to focus on expanding its market presence through both distribution and academic promotion strategies[200]. Risks and Challenges - The company faces risks related to the fluctuation of raw material prices, which can directly impact production costs and operating profits[15]. - The company’s products are subject to government pricing regulations, and recent trends indicate a continued decline in drug prices, which may affect revenue and profit[15]. - The company reported a significant risk related to the impact of the COVID-19 pandemic on offline marketing activities and rising costs, including raw materials, labor, and logistics[16]. - The company is managing raw material price volatility by establishing stable supplier relationships and maintaining flexible inventory control[119]. - The company anticipates ongoing price reductions in the pharmaceutical market and is strengthening its OTC sales channels to mitigate this risk[118]. Corporate Governance - The company has established a compensation and assessment committee responsible for formulating and reviewing the compensation policies for directors and senior management[183]. - The company’s management team remains stable, with no changes in the chairman, general manager, or financial director during the reporting period[179]. - The company experienced changes in its board, with new appointments including Zhang Jian as an independent director and Zhao Fenrong as a supervisor[180]. - Independent directors receive a pre-tax allowance of CNY 65,000 per year[183]. Shareholder Information - The total number of shares held by the top ten shareholders is 98,454,793, accounting for 67.76% of the total shares[155]. - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 85,738,590 shares, representing 59.02% of the total shares[155]. - The company raised a total of 289,598,400 yuan through public offerings, with 64,087,698.99 yuan utilized during the reporting period[165]. - The company has not changed the use of raised funds and has complied with all relevant regulations regarding fund usage[166]. Employee Information - The total number of employees decreased from 219 at the beginning of the period to 213 at the end, with a net reduction of 6 employees[187]. - The number of technical personnel increased from 44 to 47, reflecting a net addition of 3 employees in this category[187]. - The company has implemented a complete training program, enhancing employee skills through various training initiatives[188]. - The company has established a comprehensive compensation and performance evaluation system to attract and retain talent, ensuring competitive salary levels in the industry[188].